Clinical Trials Logo

AML clinical trials

View clinical trials related to AML.

Filter by:

NCT ID: NCT03622541 Completed - AML Clinical Trials

Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD

Start date: November 15, 2010
Phase: Phase 2
Study type: Interventional

Patients with refractory or relapsed acute myeloid leukemia (AML) after two courses of standard chemotherapy regimens have very limited options. Further chemotherapy is associated with significant toxicity and is generally ineffective. About 10-30% patients with AML carry a gain-of-function mutation of a gene known as Flt3 in the leukemic cells, conferring them with abnormal cellular proliferation. Sorafenib is a multi-kinase inhibitor which was licensed in Hong Kong for the treatment of advanced hepatocellular and renal cell carcinoma. The drug has also been shown to be effective against Flt3 and AML but it has not been licensed for use in this condition.

NCT ID: NCT03585517 Completed - AML Clinical Trials

Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)

Start date: July 21, 2018
Phase: Phase 1
Study type: Interventional

Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor to Patients With CD123+ AML

NCT ID: NCT03547258 Recruiting - AML Clinical Trials

Italian Non-Interventional Study of FLT3 Mutated AML Patients

FLAM
Start date: July 18, 2018
Phase:
Study type: Observational

This is an observational study involving a retrospective and prospective collection of clinical and molecular data regarding patients with AML with FLT3+ mutations

NCT ID: NCT03526666 Completed - Clinical trials for Acute Myeloid Leukemia

Ascorbic Acid Levels in MDS, AML, and CMML Patients

Start date: November 1, 2017
Phase:
Study type: Observational

This study is a non-interventional, specimen collection translational study to evaluate vitamin C levels in the peripheral blood of Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Chronic Myelomonocytic Leukemia (CMML) patients.

NCT ID: NCT03491579 Withdrawn - AML Clinical Trials

Epacadostat, Cladribine and Cytarabine (ECC) in AML

ECC
Start date: December 2018
Phase: Phase 1
Study type: Interventional

This trial assess the maximum tolerated dose (MTD) and to characterize dose-limiting toxicities (DLTs) of epacadostat when added to the cladribine/cytarabine chemotherapy in relapsed / refractory AML patients fit for intensive treatment

NCT ID: NCT03466320 Completed - AML Clinical Trials

DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2

DEPLETHINK
Start date: September 18, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This open-label Phase I study aims at assessing primarily the safety of the NKR-2 treatment administered after a non-myeloablative preconditioning regimen in r/r AML/MDS patients. This Phase I study will contain two different sequential segments. The first segment will determine the recommended investigational treatment option (schedule of preconditioning and NKR-2 dose) and the second segment will expand to a larger number of r/r AML/MDS patients.

NCT ID: NCT03465540 Terminated - Multiple Myeloma Clinical Trials

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Start date: August 17, 2018
Phase: Phase 1
Study type: Interventional

Evaluate the safety and tolerability of AMG 397. Estimate the maximum tolerated doses (MTDs) and/or biologically active doses.

NCT ID: NCT03459859 Completed - Clinical trials for Acute Myelogenous Leukemia

Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS

Start date: May 21, 2018
Phase: Phase 1
Study type: Interventional

The investigators hypothesize that the combination of Pevonedistat/Low-Dose Cytarabine (LDAC) therapy will be tolerable, that a recommended phase 2 dose of Pevonedistat in combination with LDAC will be identified, and that the combination therapy will show evidence of clinical activity in adult patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML) and Advanced Myelodysplastic Syndromes (MDS).

NCT ID: NCT03444649 Withdrawn - AML Clinical Trials

Epacadostat, Idarubicin and Cytarabine (EIC) in AML

EIC
Start date: September 2018
Phase: Phase 1
Study type: Interventional

This trial assess the maximum tolerated dose (MTD) and to characterize dose-limiting toxicities (DLTs) of epacadostat when added to the anthracycline/cytarabine combination as first-line induction treatment in AML patients fit for intensive treatment

NCT ID: NCT03315299 No longer available - AML Clinical Trials

Individual Patient Expanded Access Gilteritinib (ASP2215)

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide expanded access to ASP2215 for a single subject with refractory FLT3-mutated AML without access to comparable or alternative therapy.